Navigation Links
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Date:5/6/2008

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using Catalyst's proprietary therapeutic protease platform technologies and know-how.

CB 813 is designed to substantially enhance clot-generating activity at the site of bleeding and therefore achieve clinical efficacy with fewer and lower doses than current therapy. In established hemophilia models of acute bleeding, CB 813 has demonstrated a significant improvement in potency compared with the marketed recombinant factor VIIa product, NovoSeven(R) and a competing, second-generation product, NN1731. Catalyst intends to file an Investigational New Drug (IND) application for CB 813 and commence human clinical studies in hemophilia patients in 2009.

"Patients receiving factor VIIa therapy typically require multiple doses of drug and extended treatment times to manage acute bleeding episodes," said Gilbert C. White, II, M.D., Executive Vice President for Research and Director, Blood Research Institute, Blood Center of Wisconsin. "I am excited by the potential shown by CB 813 to improve the efficiency of treatment by achieving a faster onset and an extended duration of therapeutic benefit to patients. These advantages may significantly reduce both the number of doses and treatment time required to manage bleeding and restore normal hemostasis."

"The selection of this development candidate is an exciting milestone for Catalyst. Created to more rapidly and effectively stop bleeding, CB 813 holds great promise as a new agent in the treatment of hemophilia," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "CB 813 is representative of a new class of improved variants of factor VIIa discovered using Catalyst's proprietary protease engineering platform and know-how. Created within 12 months from program start up, CB 813 and related compounds demonstrate the power of our platform."

About Hemophilia

Hemophilia is a rare but serious bleeding disorder that results from a genetic or an acquired deficiency of a protein required for normal blood coagulation, such as factor VIII (hemophilia A) or factor IX (hemophilia B) in addition to factor VIIa for refractory hemophilia A and hemophilia B patients. Hemophilia patients suffer from potentially life-threatening spontaneous bleeding episodes and substantially prolonged bleeding times upon injury. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in permanent, disabling joint damage.

Hemophilia patients are initially treated by replacement therapy, receiving purified versions of the clotting factor in which they are deficient. However, a significant number of hemophilia A patients develop inhibitory antibodies against factor VIII and therefore become refractory to this treatment. These patients are then treated with factor VIIa, a protease enzyme that can both initiate blood clotting and, at high doses, "bypass" the factor VIII-dependent step in coagulation. Hemophilia B patients refractory to factor IX may also be treated with factor VIIa.

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates, called Alterase(TM) therapeutics, that are applicable across a broad spectrum of disease categories. Initially, Catalyst is focusing its product development efforts on Alterase drug candidates for hemophilia, age-related macular degeneration, oncology and inflammation. To date, Catalyst has established two discovery research and product development agreements with Wyeth Pharmaceuticals and Centocor Research & Development, Inc. Catalyst is privately-held with backing by leading venture firms including Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures. For more information, please visit http://www.catbio.com.

Catalyst Biosciences, Inc.

Erik Wiberg

+1.650.266.8654

ewiberg@catbio.com

BCC Partners for Catalyst Biosciences, Inc.

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662


'/>"/>
SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
2. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
3. Neurocrine Biosciences Reports First Quarter 2008 Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  Despite the recent explosion in Big ... industries to embrace Big Data due to the inherent ... medical side, organizations have begun looking to Big Data ... to adherence. --> --> ... Practices, LLC, Big Data has started informing many decisions. ...
(Date:2/5/2016)... , Feb. 5, 2016  Redwood Scientific Technologies, Inc. ... product designed to help women balance their hormones. This ... technology. Jason Cardiff , President and ... able to help the millions of women across the ... effects of imbalanced hormones. Our research and development team ...
(Date:2/5/2016)... 5, 2016  ivWatch, a medical devices company, is one ... granted by Governor Terry McAuliffe,s office. ivWatch will ... 25th at an event to be held at the Science ... honors professionals and business that have made significant contributions to ... - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Remember the old saying “rub some dirt on it”? ... author of “Calcium Bentonite Clay” the health benefits of integrating clay into a daily ... body. , A former motivational speaker, Perry A~ has since dedicated her life to ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... NV (PRWEB) , ... February 08, 2016 , ... Guruji ... February 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... true happiness. Mahendra Trivedi is known by over 250,000 people from over 40 ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... US ... Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, ... Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and ...
Breaking Medicine News(10 mins):